All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are now available for routine office visits. VCS is keeping updated on current state and local guidance for the Covid vaccine rollout plan – until then please be advised our office will not write letters of recommendation or advise patients until the state and federal guidelines are published. FOR THE LATEST UP TO DATE INFORMATION, ALERTS, VACCINE INFORMATION AND CANCELLATIONS PLEASE CLICK HERE

Clinical Trial: 20284

Trial Status: Open
Disease Type: Breast
Trial ID 20284
Sponsor ID Seattle Genetics, Inc.

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination with Trastuzumab Deruxtecan in Subjects with Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-025)

Principal Investigator
Neelima Denduluri, MD, FASCO
1 Location

Locations

Loudoun Office

Learn More About This Trial
Other Relevant Trials
Trial ID 19049
Sponsor ID Genentech, Inc.

The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a drug that looks like the study drug but contains no medication.) The usual chemotherapy in this…

Principal Investigator
Amy J. Irwin, MD
5 Locations
Trial ID 19058
Sponsor ID

CLEE011O12301C (TRIO033): A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).

Principal Investigator
Neelima Denduluri, MD, FASCO
1 Location